← Back to Clinical Trials
Recruiting NCT04611113

NCT04611113 Immunonutrition and Tolerance to Chemoradiotherapy in Patients With Head-neck Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04611113
Status Recruiting
Phase
Sponsor Fondazione IRCCS Policlinico San Matteo di Pavia
Condition Head and Neck Cancer
Study Type INTERVENTIONAL
Enrollment 86 participants
Start Date 2021-03-17
Primary Completion 2026-11-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
ImmunonutritionControl Nutritional Support

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 86 participants in total. It began in 2021-03-17 with a primary completion date of 2026-11-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the present project is to evaluate in a randomised, controlled, open-label, two parallel treatment groups pilot study, the efficacy of oral nutritional supplementation with a high-protein-high calorie mixture containing immunonutrients compared to a standard high-calorie-high-protein nutritional blend, in addition to nutritional counseling, in improving tolerance to chemoradiotherapy (CT-RT) in patients with tumours of the head and neck

Eligibility Criteria

Inclusion Criteria: * diagnosis of head-neck cancer * indication to curative or adjuvant chemoradiotherapy * availability to planned measurements and to written informed consent. Exclusion Criteria: * age \<18 years * indication to or ongoing artificial nutrition * refusal

Contact & Investigator

Central Contact

Riccardo Caccialanza, MD

✉ r.caccialanza@smatteo.pv.it

📞 0382501615

Principal Investigator

Riccardo Caccialanza, MD

PRINCIPAL INVESTIGATOR

Fondazione IRCCS Policlinico San Matteo

Frequently Asked Questions

Who can join the NCT04611113 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04611113 currently recruiting?

Yes, NCT04611113 is actively recruiting participants. Contact the research team at r.caccialanza@smatteo.pv.it for enrollment information.

Where is the NCT04611113 trial being conducted?

This trial is being conducted at Pavia, Italy.

Who is sponsoring the NCT04611113 clinical trial?

NCT04611113 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The principal investigator is Riccardo Caccialanza, MD at Fondazione IRCCS Policlinico San Matteo. The trial plans to enroll 86 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology